Corcept Therapeutics Incorporated (NASDAQ:CORT) Director Daniel N. Swisher, Jr. sold 7,500 shares of the stock in a transaction dated Monday, April 5th. The stock was sold at an average price of $24.14, for a total transaction of $181,050.00. Following the sale, the director now directly owns 7,500 shares in the company, valued at $181,050. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
CORT opened at $23.32 on Thursday. The company has a market cap of $2.74 billion, a PE ratio of 26.20 and a beta of 1.04. Corcept Therapeutics Incorporated has a twelve month low of $10.94 and a twelve month high of $31.18. The company has a 50-day moving average price of $25.20 and a 200 day moving average price of $23.58.
Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Monday, February 22nd. The biotechnology company reported $0.20 EPS for the quarter, missing the Zacks’ consensus estimate of $0.21 by ($0.01). The business had revenue of $85.74 million during the quarter, compared to analyst estimates of $91.80 million. Corcept Therapeutics had a net margin of 30.73% and a return on equity of 25.38%. The firm’s revenue was down 2.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.33 EPS. As a group, sell-side analysts expect that Corcept Therapeutics Incorporated will post 0.82 earnings per share for the current year.
A number of hedge funds have recently added to or reduced their stakes in the business. Public Sector Pension Investment Board raised its holdings in Corcept Therapeutics by 0.4% in the 4th quarter. Public Sector Pension Investment Board now owns 231,279 shares of the biotechnology company’s stock valued at $6,050,000 after acquiring an additional 870 shares during the last quarter. Planned Solutions Inc. grew its stake in shares of Corcept Therapeutics by 233.3% in the 4th quarter. Planned Solutions Inc. now owns 2,000 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 1,400 shares during the period. Swiss National Bank grew its stake in shares of Corcept Therapeutics by 0.6% in the 4th quarter. Swiss National Bank now owns 248,200 shares of the biotechnology company’s stock valued at $6,493,000 after buying an additional 1,400 shares during the period. Zebra Capital Management LLC grew its stake in shares of Corcept Therapeutics by 3.9% in the 4th quarter. Zebra Capital Management LLC now owns 46,989 shares of the biotechnology company’s stock valued at $1,229,000 after buying an additional 1,756 shares during the period. Finally, IndexIQ Advisors LLC grew its stake in shares of Corcept Therapeutics by 11.5% in the 4th quarter. IndexIQ Advisors LLC now owns 17,615 shares of the biotechnology company’s stock valued at $461,000 after buying an additional 1,818 shares during the period. Institutional investors own 75.44% of the company’s stock.
Separately, Zacks Investment Research lowered shares of Corcept Therapeutics from a “hold” rating to a “strong sell” rating and set a $25.00 target price on the stock. in a research note on Wednesday, January 20th.
Corcept Therapeutics Company Profile
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery.
Featured Story: Market Timing
Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.